Yahoo
NasdaqCM - Nasdaq Real Time Price USD

Psyence Biomedical Ltd. (PBM)

4.2400 +0.1200 (+2.91%)
At close: October 20 at 4:00:00 PM EDT
Chart Range Bar
Loading chart for PBM
  • Previous Close 4.1200
  • Open 4.0600
  • Bid 3.9000 x 200
  • Ask 6.4600 x 200
  • Day's Range 4.0600 - 4.5099
  • 52 Week Range 1.9200 - 135.9375
  • Volume 44,403
  • Avg. Volume 81,440
  • Market Cap (intraday) 16.173M
  • Beta (5Y Monthly) 1.69
  • PE Ratio (TTM) --
  • EPS (TTM) -12.5600
  • Earnings Date --
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est --

Psyence Biomedical Ltd., an integrated biopharmaceutical company, focuses on the development of botanical psilocybin-based psychedelic medicines. Its lead product candidate is NPX-5, a botanical drug candidate that is in Phase IIb clinical study for the treatment of adjustment disorder in patients with cancer in a palliative care setting. The company is based in Toronto, Canada. Psyence Biomedical Ltd. is a subsidiary of Psyence Group Inc.

psyencebiomed.com

12

Full Time Employees

March 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 10/20/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

PBM
85.59%
S&P 500 (^GSPC)
12.67%

1-Year Return

PBM
96.83%
S&P 500 (^GSPC)
14.51%

3-Year Return

PBM
100.00%
S&P 500 (^GSPC)
82.58%

5-Year Return

PBM
100.00%
S&P 500 (^GSPC)
70.02%

Statistics

View More

Valuation Measures

Annual
As of 9/23/2026
  • Market Cap

    24.03M

  • Enterprise Value

    24.60M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    1.42

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -31.33%

  • Return on Equity (ttm)

    -58.62%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -6.94M

  • Diluted EPS (ttm)

    -12.5600

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    7.44M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -4.96M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

4.2400 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: